Urinary Tract Infection Testing Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
Description
The Global Urinary Tract Infection Testing Market was valued at USD 1 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 1.9 billion by 2034. This market is expanding steadily, driven by several core factors such as the rising global burden of UTIs, the growing number of hospital-acquired infections, increased diabetes prevalence in developing countries, and the launch of innovative diagnostic solutions. As diabetes makes individuals more susceptible to urinary infections, the rising number of diabetic patients worldwide is fueling greater demand for timely and efficient diagnostic tools.
UTI testing is a clinical process that helps detect infections in various parts of the urinary system, which includes the bladder, urethra, kidneys, and ureters. The growing need for early diagnosis and accurate treatment is pushing healthcare providers to adopt advanced testing kits that support effective patient outcomes. Continuous innovation in diagnostic methods is helping address the challenge of symptomless infections in early stages, promoting the wider adoption of these technologies and boosting market expansion across healthcare facilities.
The urinalysis segment was valued at USD 494.1 million in 2024 due to its affordability, availability, and diagnostic precision. Urinalysis remains the preferred preliminary test for detecting bacterial presence and guiding subsequent clinical decisions. The segment’s momentum is further accelerated by the growing elderly population, who face a higher risk of UTIs because of physiological changes and increased use of catheters and other interventions.
The cystitis segment held a 52.1% share in 2024. Cystitis is the most widespread UTI subtype, largely impacting women due to biological factors. Frequent recurrence among patients continues to drive repeat diagnostic testing, increasing the uptake of related testing solutions. In parallel, improved public awareness around early symptoms of cystitis, supported by educational health initiatives, is encouraging more individuals to seek testing, further accelerating segment growth.
North America Urinary Tract Infection Testing Market held a 36.4% share in 2024. This leadership is attributed to the region’s robust healthcare infrastructure, early adoption of advanced medical diagnostics, and a growing UTI patient population in both the US and Canada. Rising UTI cases—particularly among older adults, women, and individuals with long-term health conditions—are contributing to the sustained expansion of the UTI testing industry in the region.
Key companies active in the Global Urinary Tract Infection Testing Market include Siemens Healthineers, ACON Laboratories, Cardinal Health, Quest Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, F. Hoffmann-La Roche, Labcorp, Randox Laboratories, Focus Laboratories, and Mankind. To solidify their market position, leading players in the urinary tract infection testing space are focusing on advancing diagnostic accuracy and speeding up testing turnaround times through automation and digital integration. Strategic partnerships with healthcare providers and diagnostic labs are expanding product availability and customer reach. Companies are also heavily investing in R&D to develop rapid testing kits and point-of-care devices that support early-stage detection. Emphasis is being placed on developing high-sensitivity assays and molecular tests that deliver reliable results even in asymptomatic cases.
UTI testing is a clinical process that helps detect infections in various parts of the urinary system, which includes the bladder, urethra, kidneys, and ureters. The growing need for early diagnosis and accurate treatment is pushing healthcare providers to adopt advanced testing kits that support effective patient outcomes. Continuous innovation in diagnostic methods is helping address the challenge of symptomless infections in early stages, promoting the wider adoption of these technologies and boosting market expansion across healthcare facilities.
The urinalysis segment was valued at USD 494.1 million in 2024 due to its affordability, availability, and diagnostic precision. Urinalysis remains the preferred preliminary test for detecting bacterial presence and guiding subsequent clinical decisions. The segment’s momentum is further accelerated by the growing elderly population, who face a higher risk of UTIs because of physiological changes and increased use of catheters and other interventions.
The cystitis segment held a 52.1% share in 2024. Cystitis is the most widespread UTI subtype, largely impacting women due to biological factors. Frequent recurrence among patients continues to drive repeat diagnostic testing, increasing the uptake of related testing solutions. In parallel, improved public awareness around early symptoms of cystitis, supported by educational health initiatives, is encouraging more individuals to seek testing, further accelerating segment growth.
North America Urinary Tract Infection Testing Market held a 36.4% share in 2024. This leadership is attributed to the region’s robust healthcare infrastructure, early adoption of advanced medical diagnostics, and a growing UTI patient population in both the US and Canada. Rising UTI cases—particularly among older adults, women, and individuals with long-term health conditions—are contributing to the sustained expansion of the UTI testing industry in the region.
Key companies active in the Global Urinary Tract Infection Testing Market include Siemens Healthineers, ACON Laboratories, Cardinal Health, Quest Diagnostics, Thermo Fisher Scientific, Bio-Rad Laboratories, Abbott Laboratories, F. Hoffmann-La Roche, Labcorp, Randox Laboratories, Focus Laboratories, and Mankind. To solidify their market position, leading players in the urinary tract infection testing space are focusing on advancing diagnostic accuracy and speeding up testing turnaround times through automation and digital integration. Strategic partnerships with healthcare providers and diagnostic labs are expanding product availability and customer reach. Companies are also heavily investing in R&D to develop rapid testing kits and point-of-care devices that support early-stage detection. Emphasis is being placed on developing high-sensitivity assays and molecular tests that deliver reliable results even in asymptomatic cases.
Table of Contents
134 Pages
- Chapter 1 Methodology and Scope
- 1.1 Market scope and definition
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Data mining sources
- 1.3.1 Global
- 1.3.2 Regional/Country
- 1.4 Base estimates and calculations
- 1.4.1 Base year calculation
- 1.4.2 Key trends for market estimation
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.6 Forecast model
- 1.7 Research assumptions and limitations
- Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
- 2.2 Key market trends
- 2.2.1 Regional
- 2.2.2 Test type
- 2.2.3 Test kit type
- 2.2.4 Application
- 2.2.5 End use
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
- Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.1.1 Supplier landscape
- 3.1.2 Value addition at each stage
- 3.1.3 Factor affecting the value chain
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing prevalence of urinary tract infections globally
- 3.2.1.2 Growing incidence of hospital-acquired urinary tract infection
- 3.2.1.3 High prevalence of diabetes in low and middle-income nations
- 3.2.1.4 Novel product launches regarding UTI testing products
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 False results associated with UTI testing
- 3.2.2.2 Stringent regulatory framework
- 3.2.3 Market opportunities
- 3.2.3.1 Expansion of rapid diagnostic technologies
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Technology and innovation landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Pricing analysis
- 3.7 Future market trends
- 3.8 Gap analysis
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
- Chapter 4 Competitive Landscape, 2024
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.2.1 North America
- 4.2.2 Europe
- 4.2.3 Asia Pacific
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategic outlook matrix
- 4.7 Key developments
- 4.7.1 Mergers and acquisitions
- 4.7.2 Partnerships and collaborations
- 4.7.3 New product launches
- 4.7.4 Expansion plans
- Chapter 5 Market Estimates and Forecast, By Test Type, 2021 - 2034 ($ Mn)
- 5.1 Key trends
- 5.2 Urinalysis
- 5.3 Urine cultures
- 5.4 Susceptibility testing
- Chapter 6 Market Estimates and Forecast, By Test Kit Type, 2021 - 2034 ($ Mn)
- 6.1 Key trends
- 6.2 Laboratory test kits
- 6.3 Home test kits
- Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)
- 7.1 Key trends
- 7.2 Urethritis
- 7.3 Cystitis
- 7.4 Pyelonephritis
- Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)
- 8.1 Key trends
- 8.2 Hospitals
- 8.3 Diagnostic laboratories
- 8.4 Homecare settings
- 8.5 Other end use
- Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 India
- 9.4.3 Japan
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- Chapter 10 Company Profiles
- 10.1 Abbott Laboratories
- 10.2 ACON Laboratories
- 10.3 Bio-Rad Laboratories
- 10.4 Cardinal Health
- 10.5 F. Hoffmann-La Roche
- 10.6 Focus Laboratories
- 10.7 LabCorp
- 10.8 Mankind
- 10.9 Quest Diagnostics
- 10.10 Randox Laboratories
- 10.11 Siemens Healthineers
- 10.12 Thermo Fisher Scientific
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
